Oncopharmpod
ASH 2025
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:29:05
- Mas informaciones
Informações:
Sinopsis
ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?
